• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Obituary Notice: Russell “Russ” Haines

    Abenza Chooses North Carolina for New Biologics Manufacturing Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Arkema Recruits Dotmatics as its R&D Digitalization Partner
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    PCI Pharma Services

    Reed-Lane

    Syngene

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Alcami

    Reed-Lane

    PCI Pharma Services

    Adare Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Challenges & Opportunities Facing Small & Emerging Biopharma Companies

    A Q&A with Christian Dowdeswell, vice president and head of commercial development for small molecules at Lonza.

    Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    Christian Dowdeswell, VP, Head of Commercial Development, Small Molecules, Lonza
    Tim Wright, Editor, Contract Pharma03.01.21
    Small and emerging pharma and biotech companies are developing the lion’s share of new drug products being approved by the FDA. But these firms face a range of challenges, including more complex molecules, more specialized and precise target product profiles and accelerated clinical milestones, often tied to funding. They also often have unique hurdles on account of their size and scale.

    What options are available to biopharma leaders to meet these often-intertwined challenges? We interviewed Christian Dowdeswell, vice president and head of commercial development for small molecules at Lonza, for insights on how contract development and manufacturing organizations (CDMOs) can help small and emerging biotech companies overcome challenges and continue developing drug products that help patients and save lives.

    Contract Pharma: What are the most important challenges in the small molecule development space today?

    Christian Dowdeswell:
    High potency remains a growth driver, with oncology being one of the therapeutic areas contributing to demand for highly potent API (HPAPI), along with antidiabetics and autoimmune therapies. These three therapy classes are the primary growth drivers globally for pharmaceutical, as well as HPAPI, consumption globally. Therapies for oncology in particular tend to target small patient populations initially, and we see many therapies being expanded into larger patient populations with related indications following the initial launch. This, coupled with extended progression-free survival, means longer periods of treatment for patients, requiring CDMOs that operate in this area to have a breadth of capabilities to ensure continued supply of product as demand fluctuates.

    Another, somewhat related area is the continued prevalence of molecules with bioavailability challenges. An estimated 90% of clinical candidates have low, poor or inconsistent solubility and dissolution.
    Dosing up is not always an option, which results in innovators looking to solution providers to equip them with enabling technologies to address poor solubility for increasingly complex molecules and target product profiles. Processing challenges can include contained particle engineering when working with HPAPI, and specialized processing parameters to accommodate higher dose loads or effectively address practically insoluble molecules.

    Additionally, the average number of chemical steps used to manufacture an NCE is estimated to have doubled in the last 10 years. The complex nature of API is demanding not only for the formulator, but also for chemical synthesis. New classes of small molecules to address previously “undruggable” targets continue to emerge, which will drive complexity further still for drug substance synthesis and the development of viable dosage forms.

    Complexity is not limited to the drug substance. It is also driving innovation in oral dosage form. For example, we are seeing inhalation formulation development across an ever-broader range of molecule classes from small molecules through to large proteins.

    CP: What role are smaller and emerging companies playing in terms of developing innovative drug products?

    Dowdeswell:
    The trend of innovation being driven by smaller companies is continuing, tied to the ongoing growth in specialty medicines. These medicines are driving industry growth, with a compound annual growth rate (CAGR) of over 10%. Small companies, which hold two-thirds of the early-stage pipeline, are increasingly filing their molecules rather than selling these assets to big pharma during clinical development. The number of approvals by the FDA for small firms was 62% in 2020, roughly doubling since 2011. Funding for biotechnology companies reached record levels in 2020, and this increased access to funds is believed to be one of the drivers for small and emerging companies to take products all the way to launch. The tendency to develop therapies for niche indications with small patient populations (~67% of FDA approvals in 2020) is undoubtedly a factor here as well.

    CP: How do the needs of smaller biopharma firms differ from those of larger ones?

    Dowdeswell:
    Small and emerging companies are typically very lean organizations, with a high focus on subject matter expertise, and business models heavily reliant on service providers. The lean organization enables companies to be very nimble and agile, it helps drive innovation and is a common attribute of many small biopharma companies. This means, however, that smaller companies have the challenge of managing service providers who have expertise and capability to support the mechanics of bringing a drug through the clinical process. In short, outsourcing behavior is frequently different. And, with an increasing number of drug programs on accelerated regulatory approval tracks, integrated services across drug substance and drug product may be considered to speed timelines as well as reduce the complexity of managing multiple vendors.

    Large companies may use service providers for a specific need where they have insufficient capability, capacity or technology gaps. On the other hand, smaller companies may look to outsource “soup to nuts,” including everything from synthesis of an API from first principles, development of a dosage form, solubility enhancement, packaging and supply to clinical sites, along with CMC support and regulatory support. Often these companies look to their service providers to guide them through some of the nuances of the clinical process in a consultative capacity.

    CP: How important is it for biopharma innovators to advance drug candidates to first in human trials quickly?

    Dowdeswell:
    An increasing number of programs are on an enhanced timeline; it has almost become the new norm. There are multiple drivers here. First, successful phase I trials can impact funding for a particular molecule while failing quickly enables a company to focus on candidates more likely to succeed. On top of that, few indications have only one company working to find a therapy and being first to market brings benefits to an innovator and their investors. There is also a strong patient component, particularly where there is an unmet clinical need. The need to run quickly places further complexity on small and emerging companies that must manage outsourced partners, cost and program risk. These factors often lead these companies to look for integrated program solutions such as those offered by Lonza. 

    CP: How should pharma and biotech companies approach accelerating candidate molecules from concept to clinic and to market?

    Dowdeswell:
    There are a number of areas to explore here. Typically, small and emerging companies rely on their service providers to supply materials to clinic. Here the nature of the relationship with service providers is important, and a few questions help define it. What business model do the organizations employ? How quickly can services be accessed? How agile is their partner to respond to inevitable changes in the program?

    Viable dosage form is often a consideration early on. Here there is a fine balance to be achieved in quickly getting through the clinical process versus time needed to develop a patient-viable dosage form. CDMOs and service providers should be able to offer services that support getting this balance right.

    Speed to clinic and market is further exacerbated by the increased chemical complexity seen in many APIs being developed now. Shorter timelines through clinic mean less time to develop efficient chemical synthesis and a less well-defined manufacturing process for an increased number of chemical steps. The same is true for drug product, with nimble CDMOs able to balance phase-appropriate approaches with scalability and minimizing downstream reformulation requirements.

    Sophisticated CDMOs may respond to these challenges with new ways of working with customers. Mindset is critical in dealing with small and emerging companies, whose limited number of molecules is their lifeblood. Each work plan must be tailored to a specific molecule, program and client need. 

    CP: Can an integrated approach, holistically incorporating drug substance and drug product, help speed product development?

    Dowdeswell:
    Undoubtedly, having a team from a single supplier working on a program removes any delay that would be related to commercial frameworks and competitive concerns versus using multiple CDMOs. Changes can be more simply planned for with a single provider than with multiple. The technical relationship between different aspects of a program can be more openly and easily addressed, be it a need to tweak the synthetic process to adapt to a new solid form, adapt an enhanced drug product intermediate to reflect the needs of a new dosage form (or vice versa) or compare different dosage forms through a single lens. So, the principles are well established that a single provider is advantageous.

    However, what we hear from our customers is that this isn’t necessarily what they find in the marketplace and that assembling disconnected sites under a single banner doesn’t make for an integrated service. True integration of such sites into an efficient network requires much work “behind the scenes,” such as processing equipment, project management, quality management systems and ERP systems and data management. It’s a holistic effort that we continually focus on making a reality. Lonza ran over 50 programs in 2020 that utilized more than one of our sites and are leveraging that experience to make our offering stronger (watch this space). One of our key learnings is that there is not a one-size-fits-all solution. Some of our customers are extremely happy having a single point of contact that manages the interactions between different sites for them; others prefer to have that control themselves.

    As an example, Lonza has a suite of solutions that cover First-in-Human clinical supply (SimpliFiH) of packaged drug product to clinic and encompassing phase appropriate options around synthesis of API, solid form services, bioavailability enhancement and drug product manufacture and supported by CMC and regulatory services. We knew that the launch of this service package was simply part of the journey and that it would be refined based on ongoing customer feedback. For example, we have recently upgraded our solid form services capabilities based on our continued evaluation of the needs of our small and emerging customer base which, consistent with the market, represent the vast majority of our First-in-Human programs. 

    Our customers use some or all of these services, specific to their needs and using simplified commercial terms to ensure that we start work in a timely fashion and advance molecules to clinic—and beyond—as quickly as possible. 

    Related Features

    • R&D
      Small Innovators & Niche CROs

      Small Innovators & Niche CROs

      Smaller CROs have the opportunity to provide a niche approach to its clients, particularly smaller sponsors who have shared synergies.
      Neil Goodman, David Bruce and Mohamed El Malt, Europital 04.01.21

    • Laboratory Testing
      Focus on Science

      Focus on Science

      How to maximize lab performance and value through comprehensive equipment management.
      Rohit Shroff, Senior Vice President, Global Lab Products, Avantor 04.01.21

    • Analytical Services | Bioanalytical Services | Laboratory Testing | R&D
      Rapid and Data Rich Chromatographic Method Development

      Rapid and Data Rich Chromatographic Method Development

      An overview of what to consider when developing chromatographic methods.
      Daniel Kirschner, Executive Director of Analytical Services, Cambrex - Durham, North Carolina 04.01.21


    • Preparing Your Post Pandemic Talent Strategy

      Preparing Your Post Pandemic Talent Strategy

      Areas for consideration for adopting the right approach to reinforce investments, optimize business and maximize your workforce.
      Neil Kelly, Managing Partner, Vector Partners 04.01.21

    • Laboratory Testing | R&D
      How Modern Near-Infrared Came to Be

      How Modern Near-Infrared Came to Be

      First region outside the visible to be discovered and last to be utilized.
      Gary E. Ritchie, Contributing Writer 04.01.21

    • APIs | Supply Chain
      Securing Your API Supply Chain: Three Keys to Success

      Securing Your API Supply Chain: Three Keys to Success

      Key considerations when outsourcing API procurement and supply chain management.
      Selwyn Lustman and Lina Cogan, LGM Pharma 04.01.21


    • Solid Dosage/Semi-solids
      Hygienic Packaging Technology

      Hygienic Packaging Technology

      Growing consumer demand for health products highlights hygienic packaging.
      John Brown, Vice President of Global Marketing, Selig 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Trends in Solid Oral Dosage Delivery

      Trends in Solid Oral Dosage Delivery

      Capsule demand continues to rise due to this delivery system’s versatility.
      Anita Solanki, Milind Biyani and Jnanadeva Bhat, PhD , ACG Capsules 03.01.21

    • Information Technology
      5 Reasons Paper Has No Place in Contract Manufacturing

      5 Reasons Paper Has No Place in Contract Manufacturing

      Digital solutions create more efficient manufacturing processes and eliminate delays.
      Dave Edwards, Chief Revenue Officer, MasterControl 03.01.21


    • Drug Delivery | Parenterals
      Injectable Drug Delivery Trends

      Injectable Drug Delivery Trends

      How medication trends are driving the shift to patient-friendly drug delivery systems.
      Peter Soelkner, Managing Director, Vetter 03.01.21

    • Pharmaceutical Manufacturing  Equipment Trends

      Pharmaceutical Manufacturing Equipment Trends

      Demand for flexibility remains the driving force behind equipment systems.
      Kristin Brooks, Managing Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Oral Solids:   Market & Technology Trends

      Oral Solids: Market & Technology Trends

      Oral solids remain the preferred route of drug delivery due to their cost-effectiveness, ease of manufacturing, and patient-friendly dose form options.
      Tim Wright, Editor, Contract Pharma 03.01.21


    • Nutraceutical Manufacturing:  Meeting the Challenges of Today, Planning for  Tomorrow

      Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow

      Companies continue balancing high demand, supply disruption, and worker safety during the pandemic.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • 2021 Contract  Manufacturing Survey

      2021 Contract Manufacturing Survey

      Our fourth annual audience poll indicates continued reliance on manufacturing partners, particularly for small businesses.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • APIs
      Small Molecule Development Trends

      Small Molecule Development Trends

      A Q&A with Cambrex Edinburgh’s site director, Mark Benger.
      Tim Wright, Editor, Contract Pharma 03.01.21

    Trending
    • Thermo Fisher Acquires PPD For $17.4B
    • Ensuring Pharma Manufacturing Quality
    • Bristol Myers Squibb Expands At Cambridge Crossing
    • Abenza Chooses North Carolina For New Biologics Manufacturing Site
    • Amgen Completes Five Prime Acquisition
    Breaking News
    • Bristol Myers Squibb Expands at Cambridge Crossing
    • Amgen Completes Five Prime Acquisition
    • Sartorius Expands in the UK
    • Obituary Notice: Russell “Russ” Haines
    • Abenza Chooses North Carolina for New Biologics Manufacturing Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    AstaReal Astaxanthin Ingredient Receives U.S. Patent Approval
    Study on Kemin’s DailyZz Botanical Blend Uncovers Sleep Quality, Next-Day Performance Benefits
    FDA’s Dr. Cara Welch Opening Speaker at the 9th AHPA Botanical Congress
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    IGL Coatings Announces Partnership in Finland
    Axalta Schedules 1Q 2021 Earnings Conference Call
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Iterative Scopes Announces IBD-Focused Scientific Advisory Board
    Vicarious Surgical, D8 Holdings Corp. Combine Operations in $1.1 Billion Deal
    FDA Grants De Novo Clearance to Medtronic’s GI Genius Model
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Bristol Myers Squibb Expands at Cambridge Crossing
    Amgen Completes Five Prime Acquisition
    Sartorius Expands in the UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Former L’Oréal Exec Joins Glossier
    Lancôme Reveals New Global Sustainability Program
    First-Ever Skincare Line Focuses on Iron To Prevent Aging
    Happi

    Latest Breaking News From Happi

    Fragrance Creators Association Celebrates P&G Executive
    Evonik Highlights Solutions for Malodor Reduction
    P&G Emphasizes Small Actions at Home To Be More Sustainable
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI reveals Eugene Singer Award winners at Virtual Spring Summit
    Monadnock Paper Mills joins SGP
    ACTEGA helps converter reach sustainability goals
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Albaad to Add Natural-Based Line in Israel
    First Quality to Discontinue Tampon Operations
    Jessup Installs New Era Coating and Laminating Line
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    BioMagnetic Sciences Names President and CEO
    Mainstay Medical Launches ReActiv8 in Australia
    Biogennix Rolls Out Agilon Strip Bone Graft
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    LG Display Cuts Down CO2-eq Emissions by 3 Million Tons in 2020
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login